​

Jasper Therapeutics (JSPR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

JSPR Stock Forecast

Jasper Therapeutics (JSPR) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $41.67, with a high of $65.00 and a low of $3.00. This represents a 2520.75% increase from the last price of $1.59.

- $13 $26 $39 $52 $65 High: $65 Avg: $41.67 Low: $3 Last Closed Price: $1.59

JSPR Stock Rating

Jasper Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 4 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 4 8 0 Strong Sell Sell Hold Buy Strong Buy

JSPR Price Target Upside V Benchmarks

TypeNameUpside
StockJasper Therapeutics2520.75%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.59$1.59$1.59
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26152--8
Dec, 25152--8
Nov, 25223--7
Oct, 25223--7
Sep, 25234--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 09, 2025Gregory RenzaRBC Capital$48.00$17.71171.03%2918.87%
Dec 05, 2024Etzer DaroutBMO Capital$63.00$21.53192.61%3862.26%
May 06, 2024Emily BodnarH.C. Wainwright$65.00$24.52165.09%3988.05%
Apr 03, 2024Gavin Clark-GartnerEvercore ISI$65.00$26.20148.09%3988.05%
Feb 07, 2023Cantor Fitzgerald$6.00$1.92212.50%277.36%
Jan 11, 2023Credit Suisse$3.00$1.6581.82%88.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 13, 2026Rodman & RenshawBuyinitialise
Jul 08, 2025RBC CapitalOutperformSector Performdowngrade
Jan 09, 2025RBC CapitalOutperformOutperformhold
Jan 08, 2025BTIGBuyBuyhold
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 15, 2024H.C. WainwrightBuyBuyhold
Oct 14, 2024OppenheimerOutperformOutperformhold
Oct 14, 2024BTIGBuyBuyhold
Oct 14, 2024Cowen & Co.BuyBuyhold
Sep 09, 2024JMP SecuritiesOutperforminitialise

Financial Forecast

EPS Forecast

$-10 $-9 $-8 $-7 $-6 $-5 $-4 $-3 $-2 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.18$-4.89----
Avg Forecast$-6.16$-4.55$-4.74$-5.01$-5.77$-5.79
High Forecast$-5.88$-4.30$-2.57$-3.56$-3.40$-5.79
Low Forecast$-6.37$-4.69$-7.01$-7.93$-9.50$-5.79
Surprise %0.32%7.47%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$4.40M$1.89M$10.71M$78.94M
High Forecast--$4.40M$1.89M$10.71M$78.94M
Low Forecast--$4.40M$1.89M$10.71M$78.94M
Surprise %------

Net Income Forecast

$-100M $-85M $-70M $-55M $-40M $-25M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-64.47M-----
Avg Forecast$-64.47M$-46.92M$-49.97M$-59.97M$-67.33M$-60.46M
High Forecast$-61.40M$-44.91M$-26.78M$-37.18M$-35.49M$-60.46M
Low Forecast$-66.52M$-48.93M$-73.15M$-82.76M$-99.17M$-60.46M
Surprise %------

JSPR Forecast FAQ

Is Jasper Therapeutics stock a buy?

Jasper Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jasper Therapeutics is a favorable investment for most analysts.

What is Jasper Therapeutics's price target?

Jasper Therapeutics's price target, set by 12 Wall Street analysts, averages $41.67 over the next 12 months. The price target range spans from $3 at the low end to $65 at the high end, suggesting a potential 2520.75% change from the previous closing price of $1.59.

How does Jasper Therapeutics stock forecast compare to its benchmarks?

Jasper Therapeutics's stock forecast shows a 2520.75% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Jasper Therapeutics over the past three months?

  • January 2026: 12.50% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.50% Strong Buy, 62.50% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 28.57% Strong Buy, 28.57% Buy, 42.86% Hold, 0% Sell, 0% Strong Sell.

What is Jasper Therapeutics’s EPS forecast?

Jasper Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.74, marking a -3.07% decrease from the reported $-4.89 in 2024. Estimates for the following years are $-5.01 in 2026, $-5.77 in 2027, and $-5.79 in 2028.

What is Jasper Therapeutics’s revenue forecast?

Jasper Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4.4M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $1.89M, followed by $10.71M for 2027, and $78.94M for 2028.

What is Jasper Therapeutics’s net income forecast?

Jasper Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-49.965M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $-59.97M in 2026, $-67.334M in 2027, and $-60.464M in 2028.